Eterna Therapeutics Acquires Exacis' Allogeneic Immuno-Oncology Platform
Eterna says it is well-positioned to develop more effective, targeted, and highly differentiated medicines to treat cancer.
Source: genengnews.com
📰 With Exaci News
With Exaci News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from With Exaci. Real-time updates on events, politics, business and more.